Axonics, Inc. (AXNX) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Devices secteur d'activité. Le siège social de l'entreprise est situé à Irvine, CA, United States. Le PDG actuel est Raymond W. Cohen.
AXNX a date d'introduction en bourse 2018-10-31, 797 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.63B.
Axonics, Inc. is a medical technology company that develops and commercializes sacral neuromodulation (SNM) systems to treat bladder and bowel dysfunction disorders, including overactive bladder, urinary incontinence, and fecal incontinence. The company's proprietary rechargeable SNM system delivers mild electrical pulses to the sacral nerve to restore normal communication between the bladder, bowel, and brain. In addition to its SNM platform, Axonics offers Bulkamid, a urethral bulking agent for treating female stress urinary incontinence. The company markets its products through a direct sales force and distributor network across the United States, United Kingdom, Germany, the Netherlands, Nordic countries, and other international markets.
